ConductScience.org, home

Comparison · NCT02292537-4a9aac2a

Nusinersen vs Sham Procedure: Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nusinersen vs Sham Procedure: Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results. Trial comparisons, record NCT02292537-4a9aac2a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02292537-4a9aac2a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0437wilson
Risk in group 20.04760.01320.158wilson
Risk difference, group 1 minus group 2-0.0476-0.1580.00806newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with the outcome on Nusinersen than on Sham Procedure21from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: sham.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1NusinersenNusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.084OG001
Group 2Sham ProcedureSham comparator on Days 1, 29, 85 and 274.242OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results
Description
The number of participants with abnormal, clinically relevant worsening, defined as participants with an ECG interpreted as abnormal and clinically relevant, with a comparison with Baseline value is reported.
Time frame
Baseline through Month 15
Population
Safety Set: All participants who were randomized and received at least 1 dose of study drug/sham procedure.

Source ClinicalTrials.gov

Trial

Title
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
NCT number
NCT02292537
Phases
PHASE3
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen, Sham procedure
Lead sponsor
Biogen
Results first posted
2018-02-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02292537-4a9aac2a